Vistagen announces positive results from exploratory phase 2a study of ph80 for acute management of the symptoms of premenstrual dysphoric disorder

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (cns) disorders, today announced that ph80, one of the company's five investigational neuroactive nasal sprays, demonstrated statistically significant improvement versus placebo in an exploratory phase 2a study for acute management of the symptoms of pre.
VTGN Ratings Summary
VTGN Quant Ranking